However, recent clinical data evaluating the efficacy and safety of tropifexor in NASH patients over 48 weeks revealed that tropifexor could inhibit ALT and HFF up to week 48, but it did not improve AST at week 12. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.